CHESTERFIELD, England, Oct. 26,
2016 /PRNewswire/ -- Mallinckrodt Pharmaceuticals
(NYSE: MNK), a leading global specialty pharmaceutical company,
will present on Thursday, Nov. 17,
2016, at the Jefferies Global Healthcare Conference at The
Waldorf Hilton, London, Aldwych,
London, WC2B 4DD, United Kingdom.
Cole Lannum, Senior Vice
President, Investor Strategy and IRO, and Daniel Speciale, Director, Investor Relations,
will represent the company in a presentation and Q&A session at
2:40 p.m. GMT.
Individuals who cannot attend the meeting in person can find
webcast information at: http://www.mallinckrodt.com/investors. A
replay will also be available following the meeting.
ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops,
manufactures, markets and distributes specialty pharmaceutical and
biopharmaceutical products and therapies, as well as nuclear
imaging products. Areas of focus include autoimmune and rare
diseases in specialty areas like neurology, rheumatology,
nephrology, pulmonology and ophthalmology; immunotherapy and
neonatal respiratory critical care therapies; analgesics and
hemostasis products; and central nervous system drugs. The
company's core strengths include the acquisition and management of
highly regulated raw materials and specialized chemistry,
formulation and manufacturing capabilities. The company's Specialty
Brands segment includes branded medicines; its Specialty Generics
segment includes specialty generic drugs, active pharmaceutical
ingredients and external manufacturing; and the Nuclear Imaging
segment includes nuclear imaging agents. To learn more about
Mallinckrodt, visit
www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Investor Relations
Coleman N.
Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com
Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
daniel.speciale@mallinckrodt.com
Media
Rhonda
Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mallinckrodt.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mallinckrodt.com
Logo - http://photos.prnewswire.com/prnh/20150105/167103LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-jefferies-2016-london-healthcare-conference-300351595.html
SOURCE Mallinckrodt Pharmaceuticals